Comparative pharmacology and toxicology of tramadol and tapentadol

被引:63
作者
Faria, J. [1 ,2 ,3 ,4 ]
Barbosa, J. [1 ,2 ,3 ,4 ]
Moreira, R. [1 ]
Queiros, O. [1 ]
Carvalho, F. [2 ]
Dinis-Oliveira, R. J. [1 ,2 ,3 ,4 ]
机构
[1] Univ Inst Hlth Sci IUCS, Inst Res & Adv Training Hlth Sci & Technol, IINFACTS, Dept Sci,CESPU,CRL, Gandra, Portugal
[2] Univ Porto, UCIBIO REQUIMTE, Fac Pharm, Lab Toxicol,Dept Biol Sci, Porto, Portugal
[3] Univ Porto, Fac Med, Dept Publ Hlth & Forens Sci, Porto, Portugal
[4] Univ Porto, Fac Med, Med Educ, Porto, Portugal
关键词
ATYPICAL OPIOID TAPENTADOL; PAIN MANAGEMENT; BLOOD-PRESSURE; RESPIRATORY DEPRESSION; N-DESMETHYLTAPENTADOL; LIQUID-CHROMATOGRAPHY; EXTENDED-RELEASE; RECEPTOR AGONIST; CEREBRAL-CORTEX; NONMEDICAL USE;
D O I
10.1002/ejp.1196
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Moderate-to-severe pain represents a heavy burden in patients' quality of life, and ultimately in the society and in healthcare costs. The aim of this review was to summarize data on tramadol and tapentadol adverse effects, toxicity, potential advantages and limitations according to the context of clinical use. We compared data on the pharmacological and toxicological profiles of tramadol and tapentadol, after an extensive literature search in the US National Library of Medicine (PubMed). Tramadol is a prodrug that acts through noradrenaline and serotonin reuptake inhibition, with a weak opioid component added by its metabolite O-desmethyltramadol. Tapentadol does not require metabolic activation and acts mainly through noradrenaline reuptake inhibition and has a strong opioid activity. Such features confer tapentadol potential advantages, namely lower serotonergic, dependence and abuse potential, more linear pharmacokinetics, greater gastrointestinal tolerability and applicability in the treatment of chronic and neuropathic pain. Although more studies are needed to provide clear guidance on the opioid of choice, tapentadol shows some advantages, as it does not require CYP450 system activation and has minimal serotonergic effects. In addition, it leads to less side effects and lower abuse liability. However, invivo and invitro studies have shown that tramadol and tapentadol cause similar toxicological damage. In this context, it is important to underline that the choice of opioid should be individually balanced and a tailored decision, based on previous experience and on the patient's profile, type of pain and context of treatment. SignificanceThis review underlines the need for a careful prescription of tramadol and tapentadol. Although both are widely prescribed synthetic opioid analgesics, their toxic effects and potential dependence are not completely understood yet. In particular, concerning tapentadol, further research is needed to better assess its toxic effects.
引用
收藏
页码:827 / 844
页数:18
相关论文
共 133 条
  • [51] Giorgi M., 2012, American Journal of Animal and Veterinary Sciences, V7, P7
  • [52] Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs
    Giorgi, Mario
    Meizler, Alon
    Mills, Paul C.
    [J]. VETERINARY JOURNAL, 2012, 194 (03) : 309 - 313
  • [53] Identification of tramadol and its metabolites in blood from drug-related deaths and drug-impaired drivers
    Goeringer, KE
    Logan, BK
    Christian, GD
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 1997, 21 (07) : 529 - 537
  • [54] High-dose tramadol in comparison to low-dose morphine for cancer pain relief
    Grond, S
    Radbruch, L
    Meuser, T
    Loick, G
    Sabatowski, R
    Lehmann, KA
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1999, 18 (03) : 174 - 179
  • [55] Clinical pharmacology of tramadol
    Grond, S
    Sablotzki, A
    [J]. CLINICAL PHARMACOKINETICS, 2004, 43 (13) : 879 - 923
  • [56] Targeting multiple opioid receptors - improved analgesics with reduced side effects?
    Guenther, Thomas
    Dasgupta, Pooja
    Mann, Anika
    Miess, Elke
    Kliewer, Andrea
    Fritzwanker, Sebastian
    Steinborn, Ralph
    Schulz, Stefan
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (14) : 2857 - 2868
  • [57] Prescription Opioid Use, Misuse, and Use Disorders in US Adults: 2015 National Survey on Drug Use and Health
    Han, Beth
    Compton, Wilson M.
    Blanco, Carlos
    Crane, Elizabeth
    Lee, Jinhee
    Jones, Christopher M.
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (05) : 293 - +
  • [58] Tapentadol in Pain Management A μ-Opioid Receptor Agonist and Noradrenaline Reuptake Inhibitor
    Hartrick, Craig T.
    Rozek, Richard J.
    [J]. CNS DRUGS, 2011, 25 (05) : 359 - 370
  • [59] A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans
    Jeong, I. D.
    Camilleri, M.
    Shin, A.
    Iturrino, J.
    Boldingh, A.
    Busciglio, I.
    Burton, D.
    Ryks, M.
    Rhoten, D.
    Zinsmeister, A. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (09) : 1088 - 1096
  • [60] Drug-related celebrity deaths: A cross-sectional study
    Just, Johannes M.
    Bleckwenn, Markus
    Schnakenberg, Rieke
    Skatulla, Philipp
    Weckbecker, Klaus
    [J]. SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2016, 11